Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations
- PMID: 30607767
- PMCID: PMC6946768
- DOI: 10.1007/s12079-018-00500-8
Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations
Abstract
Diabetic retinopathy (DR) is considered as a diabetes-related complication that can render severe visual impairments and is also a risk factor for acquired blindness in both developed as well as developing countries. Through fibrovascular epiretinal membranes (ERMs), this condition can similarly lead to tractional retinal detachment. Laboratory efforts evaluating the DR pathogenesis can be provided by ocular vitreous fluid and ERMs resulting from vitrectomy. The clinical stages of DR are significantly associated with expression levels of certain chemokines, including monocyte chemotactic protein-1 (MCP-1) in the intraocular fluid. The MCP-1 is also a known potent chemotactic factor for monocytes and macrophages that can stimulate them to produce superoxide and other mediators. Following hyperglycemia, retinal pigmented epithelial (RPE) cells, endothelial cells, and Müller's glial cells are of utmost importance for MCP-1 production, and vitreous MCP-1 levels rise in patients with DR. Increased expression of the MCP-1 in the eyes can also play a significant role in the pathogenesis of DR. In this review, current clinical and laboratory progress achieved on the MCP-1 and the DR concerning neovascularization and inflammatory responses in vitreous and/or aqueous humor of DR patients was summarized. It was suggested that further exploration of the MCP-1/CCR2 axis association between clinical stages of DR and expression levels of inflammatory and angiogenic cytokines and chemokines, principally the MCP-1 might lead to potential therapies aiming at neutralizing antibodies and viral vectors.
Keywords: CCL2; DR; MCP-1; PDR; Retinopathy.
Conflict of interest statement
All of the authors declared no conflict of interest.
Figures

Similar articles
-
Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion.Jpn J Ophthalmol. 2011 May;55(3):256-263. doi: 10.1007/s10384-011-0004-8. Epub 2011 May 3. Jpn J Ophthalmol. 2011. PMID: 21538000
-
Role of cytokines and trophic factors in the pathogenesis of diabetic retinopathy.Curr Diabetes Rev. 2005 Feb;1(1):73-81. doi: 10.2174/1573399052952596. Curr Diabetes Rev. 2005. PMID: 18220584 Review.
-
Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.Eur Cytokine Netw. 2006 Sep;17(3):155-65. Eur Cytokine Netw. 2006. PMID: 17194635
-
Elevated Activating Transcription Factor 4 and Glucose-Regulated 78 Kda Protein Levels Correlate with Inflammatory Cytokines in the Aqueous Humor and Vitreous of Proliferative Diabetic Retinopathy.Curr Eye Res. 2017 Aug;42(8):1202-1208. doi: 10.1080/02713683.2017.1297998. Epub 2017 May 12. Curr Eye Res. 2017. PMID: 28497987
-
Immune responses to injury and their links to eye disease.Transl Res. 2021 Oct;236:52-71. doi: 10.1016/j.trsl.2021.05.005. Epub 2021 May 27. Transl Res. 2021. PMID: 34051364 Free PMC article. Review.
Cited by
-
Cell and molecular targeted therapies for diabetic retinopathy.Front Endocrinol (Lausanne). 2024 Jun 14;15:1416668. doi: 10.3389/fendo.2024.1416668. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38948520 Free PMC article. Review.
-
Role of myeloid cells in ischemic retinopathies: recent advances and unanswered questions.J Neuroinflammation. 2024 Mar 7;21(1):65. doi: 10.1186/s12974-024-03058-y. J Neuroinflammation. 2024. PMID: 38454477 Free PMC article. Review.
-
Exploring Molecular Signatures Associated with Inflammation and Angiogenesis in the Aqueous Humor of Patients with Non-Proliferative Diabetic Retinopathy.Int J Mol Sci. 2025 Jul 4;26(13):6461. doi: 10.3390/ijms26136461. Int J Mol Sci. 2025. PMID: 40650239 Free PMC article.
-
Aqueous humor monocyte chemoattractant protein-1 predicted long-term visual outcome of proliferative diabetic retinopathy undergone intravitreal injection of bevacizumab and vitrectomy.PLoS One. 2021 Mar 5;16(3):e0248235. doi: 10.1371/journal.pone.0248235. eCollection 2021. PLoS One. 2021. PMID: 33667285 Free PMC article. Clinical Trial.
-
Endothelial Dysfunction in Diabetic Retinopathy.Front Endocrinol (Lausanne). 2020 Sep 4;11:591. doi: 10.3389/fendo.2020.00591. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33013692 Free PMC article. Review.
References
-
- Adamis AP, Berman AJ (2008) Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars in immunopathology. Springer - PubMed
-
- Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–1487. - PubMed
-
- Antunica AG, Karaman K, Znaor L, Sapunar A, Buško V, Puzović V. IL-12 concentrations in the aqueous humor and serum of diabetic retinopathy patients. Graefes Arch Clin Exp Ophthalmol. 2012;250(6):815–821. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous